Cardax Inc. (OTCQB: CDXI), a company that devotes substantially all of its efforts to developing and commercializing dietary supplements and pharmaceuticals, has reported its revenues for the first quarter of 2018, it was reported yesterday.
Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased almost three-fold from USD107,990 in the first quarter of 2017 to USD313,310 in the first quarter of 2018.
ZanthoSyn was the top selling product at General Nutrition Corporation stores in Hawaii for the second consecutive quarter.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva